Literature DB >> 7104173

Enhanced metabolism of mexiletine after phenytoin administration.

E J Begg, P M Chinwah, C Webb, R O Day, D N Wade.   

Abstract

1 Unexpectedly low plasma concentrations of mexiletine were observed in three patients treated with mexiletine and concurrently taking phenytoin. 2 Six healthy volunteers were given a single oral dose of mexiletine (400 mg), before and after 1 week of phenytoin administration (300 mg/day). 3 The mean +/- s.d. area under the plasma mexiletine concentration-time curve decreased from 17.67 +/- 6.21 to 8.01 +/- 3.64 micrograms ml-1 h (P less than 0.003). 4 The mean +/- s.d. half-life of elimination of mexiletine decreased from 17.2 +/- 5.26 to 8.4 +/- 4.17 h (P less than 0.02) 5 The suggested mechanism of the interaction is hepatic mixed-function oxidase enzyme induction by phenytoin. 6 The interaction is likely to be clinically significant.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7104173      PMCID: PMC1427733          DOI: 10.1111/j.1365-2125.1982.tb01965.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  The distribution, metabolism and excretion of mexiletine in man.

Authors:  A H Beckett; E C Chidomere
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

2.  Variable pharmacokinetics of mexiletine.

Authors:  C M Kaye; M A Kiddie; P Turner
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

3.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

4.  Interaction of quinidine with anticonvulsant drugs.

Authors:  J L Data; G R Wilkinson; A S Nies
Journal:  N Engl J Med       Date:  1976-03-25       Impact factor: 91.245

5.  Malabsorption of frusemide caused by phenytoin.

Authors:  A Fine; I S Henderson; D R Morgan; W J Tilstone
Journal:  Br Med J       Date:  1977-10-22

6.  Measurement of plasma mexiletine concentrations.

Authors:  J G Kelly
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

7.  Absorption, distribution and elimination of mexiletine.

Authors:  L F Prescott; A Pottage; J A Clements
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

8.  Treatment of ventricular arrhythmias with mexiletine (Kö 1173).

Authors:  R G Talbot; J Nimmo; D G Julian; R A Clark; J M Neilson; L F Prescott
Journal:  Lancet       Date:  1973-08-25       Impact factor: 79.321

9.  The clinical pharmacology of mexiletine.

Authors:  N P Campbell; J G Kelly; A A Adgey; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1978-08       Impact factor: 4.335

10.  Mexiletine (Kö 1173) in the management of ventricular dysrhythmias.

Authors:  N P Campbell; J G Kelly; R G Shanks; N C Chaturvedi; J E Strong; J F Pantridge
Journal:  Lancet       Date:  1973-08-25       Impact factor: 79.321

View more
  7 in total

Review 1.  Pharmacokinetic drug interactions with phenytoin (Part II).

Authors:  R L Nation; A M Evans; R W Milne
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of mexiletine.

Authors:  L Labbé; J Turgeon
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

Review 3.  Antiarrhythmic agents: drug interactions of clinical significance.

Authors:  T C Trujillo; P E Nolan
Journal:  Drug Saf       Date:  2000-12       Impact factor: 5.606

4.  Sodium channel slow inactivation as a therapeutic target for myotonia congenita.

Authors:  Kevin R Novak; Jennifer Norman; Jacob R Mitchell; Martin J Pinter; Mark M Rich
Journal:  Ann Neurol       Date:  2015-01-09       Impact factor: 10.422

Review 5.  Clinical pharmacokinetics of the newer antiarrhythmic agents.

Authors:  A M Gillis; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

Review 6.  Mexiletine. A review of its therapeutic use in painful diabetic neuropathy.

Authors:  B Jarvis; A J Coukell
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

7.  Cirrhosis of the liver markedly impairs the elimination of mexiletine.

Authors:  P J Pentikäinen; S Hietakorpi; M O Halinen; L M Lampinen
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.